Literature DB >> 32394881

Prevalence of Hepatitis C Virus in an Endemic Area of Thailand: Burden Assessment toward HCV Elimination.

Rujipat Wasitthankasem1,2,3, Napaporn Pimsingh4, Khuandao Treesun4, Nawarat Posuwan1, Preeyaporn Vichaiwattana1, Chompoonut Auphimai1, Ilada Thongpan1, Sissades Tongsima2,3, Sompong Vongpunsawad1, Yong Poovorawan1.   

Abstract

Chronic hepatitis C virus (HCV) infection can lead to liver cirrhosis and hepatocellular carcinoma. To eliminate HCV infection in an endemic area, an epidemiological baseline of the current HCV infection in the population is required. We therefore aimed to evaluate the HCV burden in the Thai Province of Phetchabun, which has the highest HCV infection rate in the country. Toward this, a province-wide district-based representative sampling of 4,769 individuals ages 35-64 years previously shown to represent high-risk age-groups were tested for anti-HCV antibodies using the automated chemiluminescent microparticle assays. Active HCV infection and subsequent genotyping were determined from serologically reactive samples by amplification of the HCV core gene. We found that 6.9% (327/4,769) were anti-HCV positive, of which 75.8% (248/327) had detectable HCV RNA and 5.8% (19/327) were in the presence of hepatitis B virus coinfection. Nucleotide sequencing and phylogenetic analysis revealed that HCV genotype 6 was the most prevalent (41%, 101/248), followed by genotype 3 (31%, 78/248), and genotype 1 (28%, 69/248). Socioeconomic and demographic factors including male gender, education, and agricultural work were associated with HCV seropositivity. From these results, we defined the regional HCV genotypes and estimated the HCV burden necessary toward the implementation of pan-genotypic direct-acting antivirals, which may be appropriate and effective toward the diversity of genotypes identified in this study. Micro-elimination of HCV in Phetchabun may serve as a model for a more comprehensive coverage of HCV treatment in Thailand.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32394881      PMCID: PMC7356443          DOI: 10.4269/ajtmh.19-0817

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  29 in total

1.  High genetic diversity including potential new subtypes of hepatitis C virus genotype 6 in Lao People's Democratic Republic.

Authors:  J M Hübschen; P Jutavijittum; T Thammavong; B Samountry; A Yousukh; K Toriyama; A Sausy; C P Muller
Journal:  Clin Microbiol Infect       Date:  2011-09-29       Impact factor: 8.067

Review 2.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-12-16

3.  Seroprevalence and genotype of hepatitis C virus among immigrant workers from Cambodia and Myanmar in Thailand.

Authors:  Srunthron Akkarathamrongsin; Kesmanee Praianantathavorn; Nisachol Hacharoen; Apiradee Theamboonlers; Pisit Tangkijvanich; Yong Poovorawan
Journal:  Intervirology       Date:  2010-08-06       Impact factor: 1.763

4.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

Review 5.  Global epidemiology and genotype distribution of the hepatitis C virus infection.

Authors:  Erin Gower; Chris Estes; Sarah Blach; Kathryn Razavi-Shearer; Homie Razavi
Journal:  J Hepatol       Date:  2014-07-30       Impact factor: 25.083

6.  Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.

Authors:  Edward J Gane; Robert H Hyland; Di An; Evguenia Svarovskaia; Phillip S Pang; Diana Brainard; Catherine A Stedman
Journal:  Gastroenterology       Date:  2015-08-07       Impact factor: 22.682

7.  Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era.

Authors:  Kittiyod Poovorawan; Wirichada Pan-Ngum; Lisa J White; Ngamphol Soonthornworasiri; Polrat Wilairatana; Rujipat Wasitthankasem; Pisit Tangkijvanich; Yong Poovorawan
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

8.  Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy.

Authors:  Rujipat Wasitthankasem; Preeyaporn Vichaiwattana; Nipaporn Siripon; Nawarat Posuwan; Chompoonut Auphimai; Sirapa Klinfueng; Napha Thanetkongtong; Viboonsak Vuthitanachot; Supapith Saiyatha; Chaiwat Thongmai; Saowakon Sochoo; Panthip Sukthong; Kittiyod Poovorawan; Pisit Tangkijvanich; Yong Poovorawan
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

9.  Progress in Testing for and Treatment of Hepatitis C Virus Infection Among Persons Who Inject Drugs - Georgia, 2018.

Authors:  Ketevan Stvilia; Philip R Spradling; Alexander Asatiani; Maka Gogia; Khatuna Kutateladze; Maia Butsashvili; Jaba Zarkua; Tengiz Tsertsvadze; Lali Sharvadze; Maia Japaridze; Tinatin Kuchuloria; Lia Gvinjilia; Irinka Tskhomelidze; Amiran Gamkrelidze; Irma Khonelidze; David Sergeenko; Shaun Shadaker; Francisco Averhoff; Muazzam Nasrullah
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-07-26       Impact factor: 17.586

10.  An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project.

Authors:  Gamal Shiha; Ammal M Metwally; Reham Soliman; Mohamed Elbasiony; Nabiel N H Mikhail; Philippa Easterbrook
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-07-18
View more
  4 in total

1.  Prescreening with a Rapid Diagnostic Test Followed by a Confirmatory Qualitative Nucleic Acid Test Can Simplify Hepatitis C Diagnosis.

Authors:  Rujipat Wasitthankasem; Nawarat Posuwan; Napaporn Pimsingh; Wijittra Phaengkha; Saranya Ngamnimit; Preeyaporn Vichaiwattana; Ilada Thongpan; Sissades Tongsima; Sompong Vongpunsawad; Yong Poovorawan
Journal:  Am J Trop Med Hyg       Date:  2022-02-28       Impact factor: 3.707

2.  Hepatitis C viraemic and seroprevalence and risk factors for positivity in Northwest Cambodia: a household cross-sectional serosurvey.

Authors:  Emily Lynch; Gregoire Falq; Chhorvy Sun; Pharm D Tek Bunchhoeung; Helena Huerga; Anne Loarec; Jean-Phillipe Dousset; Tonia Marquardt; Mickael Le Paih; David Maman
Journal:  BMC Infect Dis       Date:  2021-02-26       Impact factor: 3.090

3.  Hepatitis C seroprevalence among people living with HIV/AIDS and pregnant women in four provinces in Cambodia: an integrated bio-behavioral survey.

Authors:  Phearavin Pheng; Laurence Meyer; Olivier Ségéral; Phalla Chea; Siyan Yi; Sovannary Tuot; John M Kaldor; Vonthanak Saphonn
Journal:  BMC Infect Dis       Date:  2022-02-22       Impact factor: 3.090

4.  A surveillance for hepatitis C virus infection in northeastern, Thailand: a 10-year cohort.

Authors:  Tanita Suttichaimongkol; Chitchai Rattananukrom; Arthit Wongsaensook; Wattana Sukeepaisarnjaroen; Kittisak Sawanyawisuth
Journal:  J Prev Med Hyg       Date:  2022-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.